The Gut Microbiota of Critically Ill Patients With COVID-19.


Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2021
Historique:
received: 21 02 2021
accepted: 03 06 2021
entrez: 16 7 2021
pubmed: 17 7 2021
medline: 21 7 2021
Statut: epublish

Résumé

The SARS-CoV-2-associated COVID-19 pandemic has shaken the global healthcare system. Although the best-known symptoms are dry cough and pneumonia, viral RNA has been detected in the stool and about half of COVID-19 patients exhibit gastrointestinal upset. In this scenario, special attention is being paid to the possible role of the gut microbiota (GM). Fecal samples from 69 COVID-19 patients from three different hospitals of Bologna (Italy) were analyzed by 16S rRNA gene-based sequencing. The GM profile was compared with the publicly available one of healthy age- and gender-matched Italians, as well as with that of other critically ill non-COVID-19 patients. The GM of COVID-19 patients appeared severely dysbiotic, with reduced diversity, loss of health-associated microorganisms and enrichment of potential pathogens, particularly

Identifiants

pubmed: 34268136
doi: 10.3389/fcimb.2021.670424
pmc: PMC8276076
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

670424

Informations de copyright

Copyright © 2021 Gaibani, D’Amico, Bartoletti, Lombardo, Rampelli, Fornaro, Coladonato, Siniscalchi, Re, Viale, Brigidi, Turroni and Giannella.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):495-502
pubmed: 33389263
Lancet Microbe. 2020 May;1(1):e11
pubmed: 32835323
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Bioinformatics. 2005 Jun 1;21(11):2789-90
pubmed: 15797915
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
BMC Bioinformatics. 2012 Feb 14;13:31
pubmed: 22333067
Nutrients. 2019 Dec 04;11(12):
pubmed: 31817158
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Mayo Clin Proc. 2020 Aug;95(8):1632-1648
pubmed: 32753138
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Biotechniques. 2004 May;36(5):808-12
pubmed: 15152600
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Microbiome. 2017 Mar 24;5(1):39
pubmed: 28340597
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):534-535
pubmed: 32304638
Gastroenterology. 2020 Oct;159(4):1302-1310.e5
pubmed: 32598884
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Med Chem. 2018 Jan 11;61(1):47-61
pubmed: 28745893
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Gastroenterol. 2020 Jun;115(6):916-923
pubmed: 32301761
Gut. 2016 Nov;65(11):1812-1821
pubmed: 26416813
Curr Biol. 2016 Jun 6;26(11):1480-5
pubmed: 27185560
Gut Microbes. 2020 Nov 9;12(1):1707610
pubmed: 31924126
Crit Care Med. 2021 Jan 1;49(1):e31-e40
pubmed: 33122577
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Clin Microbiol Infect. 2021 Jan;27(1):9-11
pubmed: 32979569
United European Gastroenterol J. 2020 Aug;8(7):775-781
pubmed: 32438878
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Nat Med. 2018 Dec;24(12):1809-1814
pubmed: 30323331
Clin Infect Dis. 2020 Dec 17;71(10):2669-2678
pubmed: 32497191
Gut. 2021 Apr 8;:
pubmed: 33833065
Cell. 2016 Jun 2;165(6):1332-1345
pubmed: 27259147
Gut. 2021 Feb;70(2):276-284
pubmed: 32690600
Clin Microbiol Infect. 2020 Nov;26(11):1545-1553
pubmed: 32781244
Nat Med. 2018 Apr 10;24(4):392-400
pubmed: 29634682
Nat Commun. 2017 Dec 5;8(1):1784
pubmed: 29209090

Auteurs

Paolo Gaibani (P)

Microbiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, IRCCS St. Orsola Hospital and University of Bologna, Bologna, Italy.

Federica D'Amico (F)

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Michele Bartoletti (M)

Infectious Diseases Unit, Department of Medical and Surgical Sciences, IRCCS St. Orsola Hospital, Bologna, Italy.

Donatella Lombardo (D)

Microbiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, IRCCS St. Orsola Hospital and University of Bologna, Bologna, Italy.

Simone Rampelli (S)

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.

Giacomo Fornaro (G)

Infectious Diseases Unit, Department of Medical and Surgical Sciences, IRCCS St. Orsola Hospital, Bologna, Italy.

Simona Coladonato (S)

Infectious Diseases Unit, Department of Medical and Surgical Sciences, IRCCS St. Orsola Hospital, Bologna, Italy.

Antonio Siniscalchi (A)

Intensive Care Unit, Department of Medical and Surgical Sciences, IRCCS St. Orsola Hospital and University of Bologna, Bologna, Italy.

Maria Carla Re (MC)

Microbiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, IRCCS St. Orsola Hospital and University of Bologna, Bologna, Italy.

Pierluigi Viale (P)

Infectious Diseases Unit, Department of Medical and Surgical Sciences, IRCCS St. Orsola Hospital, Bologna, Italy.

Patrizia Brigidi (P)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Silvia Turroni (S)

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.

Maddalena Giannella (M)

Infectious Diseases Unit, Department of Medical and Surgical Sciences, IRCCS St. Orsola Hospital, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH